GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Goodwill-to-Asset

MAIA (MAIA Biotechnology) Goodwill-to-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. MAIA Biotechnology's Goodwill for the quarter that ended in Jun. 2024 was $0.00 Mil. MAIA Biotechnology's Total Assets for the quarter that ended in Jun. 2024 was $12.02 Mil.


MAIA Biotechnology Goodwill-to-Asset Historical Data

The historical data trend for MAIA Biotechnology's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Goodwill-to-Asset Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
- - - -

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MAIA Biotechnology's Goodwill-to-Asset

For the Biotechnology subindustry, MAIA Biotechnology's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's Goodwill-to-Asset falls into.



MAIA Biotechnology Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

MAIA Biotechnology's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/7.567
=

MAIA Biotechnology's Goodwill to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Goodwill to Asset (Q: Jun. 2024 )=Goodwill/Total Assets
=0/12.02
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology  (AMEX:MAIA) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


MAIA Biotechnology Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606